Contact
    Start Publications Nanopatterned Cadmium Selenide Langmuir–Blodgett Platform for ...
    ←  Publication Finder
    KSV NIMA

    Nanopatterned Cadmium Selenide Langmuir–Blodgett Platform for Leukemia Detection

    Year: 2012

    Journal: Anal. Chem., 2012, 84 (7), 3082–3089, 20131009

    Authors: Aditya Sharma, Chandra M. Pandey, Zimple Matharu, Udit Soni, Sameer Sapra, Gajjala Sumana, Manoj K. Pandey, Tathagat Chatterjee, Bansi D. Malhotra

    Organizations: Department of Science & Technology Centre on Biomolecular Electronics, Biomedical Instrumentation Section, Materials Physics & Engineering Division, National Physical Laboratory (Council of Scientific & Industrial Research), Dr K. S. Krishnan Marg, New Delhi 110012, India; Department of Chemistry, Indian Institute of Technology Delhi, Hauz Khas, New Delhi 110016, India; Department of Pathology, Army Hospital (Research & Referral), Delhi Cantt, New Delhi 110010, India; Centre for NanoBioengineering & SpinTronics, Chungnam National University, 220 Gung-Dong, Yuseong-Gu, Daejeon, 305-764, Korea; Department of Biotechnology, Delhi Technological University, Delhi 110042, India

    We present results of the studies relating to preparation of Langmuir–Blodgett (LB) monolayers of tri-n-octylphosphine oxide-capped cadmium selenide quantum dots (QCdSe) onto indium–tin oxide (ITO) coated glass substrate. The monolayer behavior has been studied at the air–water interface under various subphase conditions. This nanopatterned platform has been explored to fabricate an electrochemical DNA biosensor for detection of chronic myelogenous leukemia (CML) by covalently immobilizing the thiol-terminated oligonucleotide probe sequence via a displacement reaction. The results of electrochemical response studies reveal that this biosensor can detect target DNA in the range of 10–6 to 10–14 M within 120 s, has a shelf life of 2 months, and can be used about 8 times. Further, this nucleic acid sensor has been found to distinguish the CML-positive and the control negative clinical patient samples.